Genmab Expands Capital Through Employee Warrant Exercise
Company Announcement
Genmab A/S (Nasdaq: GMAB) recently announced a capital increase of 10,058 shares due to the exercise of employee warrants.
This increase is conducted without any preemption rights for existing shareholders, allowing shares to be subscribed for in cash at varying prices. Here’s a breakdown of the new shares exercised:
- 709 shares at DKK 962.00
- 3,729 shares at DKK 1,025.00
- 415 shares at DKK 1,050.00
- 200 shares at DKK 1,147.50
- 335 shares at DKK 1,161.00
- 3,116 shares at DKK 1,210.00
- 1,554 shares at DKK 1,362.50
The proceeds from this initiative are projected to be about DKK 11.4 million, correlating to roughly 0.02% of the company's total share capital.
The new shares are standard and transferable without preferential rights, allowing holders to receive dividends and participate fully in the company's progress right from the point of subscription. Once registered with the Danish Business Authority, these shares will be listed on Nasdaq Copenhagen.
Understanding Genmab’s Vision
About Genmab
Genmab is a pioneering biotechnology company with a mission focused on innovating treatments for patients through advanced antibody therapeutics. Over its 25 years of existence, Genmab has cultivated an exceptional team dedicated to groundbreaking research and clinical trials—fostering innovations in next-generation antibody technology platforms and building a rich pipeline including bispecific T-cell engagers and antibody-drug conjugates.
By 2030, Genmab aims to significantly impact cancer care and other serious ailments with what it terms "knock-your-socks-off" (KYSO) antibody medicines.
Geographical Footprint and Innovations
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has extended its reach globally, establishing operations across North America, Europe, and the Asia Pacific. The company thrives on collaboration, focusing on transforming scientific advancements into tangible therapies for patients worldwide.
Recent innovative projects include next-generation immune checkpoint modulators, which represent crucial advancements in cancer treatment efficacy. The company is enthusiastic about the future, harnessing data and translational sciences to enhance the efficacy and safety of its therapies.
Proceeds from the Capital Increase
The funds generated from the warrant exercise will be utilized for further research and development, supporting Genmab's ongoing commitment to innovation in healthcare. These strategic investments are essential for sustaining operational growth and enhancing shareholder value as the company progresses.
Company Contacts
Inquiries about Genmab can be directed to:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What is the purpose of the capital increase by Genmab?
The capital increase is intended to raise funds from employee warrant exercises, contributing to further research and development efforts.
How many shares are being increased?
A total of 10,058 shares are being added to Genmab's capital through this process.
What will the proceeds from this increase be used for?
Proceeds of approximately DKK 11.4 million will primarily support innovation in product development and company growth.
When will the new shares be listed?
The new shares will be listed on Nasdaq Copenhagen shortly after registration with the Danish Business Authority.
What is Genmab's long-term goal?
Genmab aims to enhance the lives of patients through its innovative antibody therapies, positioning itself as a leader in biopharmaceutical advancements by 2030.
